Audentes starts therapy development for DMD and myotonic dystrophy

Published Date
Beatriz Bustillo Ramirez
Orange box stating: Breaking news research

Audentes Therapeutics has announced that it will begin the development of new genetic medicines for Duchenne muscular dystrophy and myotonic dystrophy type 1. These therapies will aim to address the underlying causes of these conditions by delivering genetic information into the body. Audentes currently has an AAV-based gene therapy for myotubular myopathy in early-stage clinical trial.

For more information read Audentes’ community letter and press release.

If you have any questions about this news story or any other muscular dystrophy research, please contact the MDUK Research Line on 020 7803 4813 or email

Keep in touch